双氢青蒿素靶向NQO1促进非小细胞肺癌铁死亡相关氧化应激
本研究探讨双氢青蒿素(DHA)在非小细胞肺癌(NSCLC)中诱导铁死亡的分子机制。通过网络药理学与转录组学筛选出NQO1为核心靶点,表面等离子共振证实DHA与NQO1直接结合(KD=7.61×10−6 M)。DHA抑制NQO1表达,在A549和PC9细胞中引发ROS爆发、脂质过氧化、Fe2+累积、GSH/GSSG耗竭、MDA升高及GPX4失活等铁死亡特征,NQO1过表达可部分逆转上述效应,体内实验显示DHA抑瘤作用可被NQO1过表达部分逆转。
要点
- DHA通过抑制NQO1表达诱导NSCLC细胞铁死亡相关氧化应激。
- NQO1过表达部分逆转DHA效应,NQO1敲低模拟DHA诱导的铁死亡。
- GPX4过表达可部分挽救NQO1缺失所致铁死亡表型。
核心结论
- DHA通过直接结合NQO1并抑制其表达,促进NSCLC细胞铁死亡相关氧化应激,从而抑制肿瘤生长。
研究设计与样本
- 采用网络药理学与转录组学整合分析筛选青蒿铁死亡相关靶点,结合分子对接与分子动力学模拟进行靶点优先级排序。
- 利用表面等离子共振(SPR)和细胞热转移试验(CETSA)评估DHA与NQO1的相互作用。
- 在A549和PC9细胞中检测DHA对铁死亡表型及氧化还原稳态的影响,并开展NQO1过表达、NQO1敲低及GPX4挽救实验。
- 在小鼠肿瘤模型中评估DHA抗肿瘤活性及NQO1相关效应。
主要发现
- 网络药理学鉴定出青蒿15种活性成分和61个NSCLC相关治疗靶点,富集于ROS相关和铁死亡相关通路。
- 在10个铁死亡相关核心靶点中,基于疾病相关性、预测的DHA相互作用、选择性蛋白抑制及计算与实验证据,NQO1被优先选定。
- SPR支持DHA与NQO1直接结合,KD=7.61×10−6 M。
- DHA通过转录抑制和增强蛋白降解抑制NQO1表达。
- DHA在A549和PC9细胞中诱导ROS爆发、LPO和Fe2+累积、GSH/GSSG耗竭、MDA升高及GPX4失活等铁死亡标志;NQO1过表达部分逆转这些效应,NQO1敲低模拟DHA诱导的铁死亡反应;GPX4过表达部分挽救NQO1缺失诱导的铁死亡表型。
关键数值与推荐
- DHA与NQO1直接结合的KD值为7.61×10−6 M(SPR法)。
- 网络药理学鉴定青蒿15种活性成分和61个NSCLC相关治疗靶点,其中10个为铁死亡相关核心靶点。
临床怎么用
- DHA可能作为靶向NQO1诱导铁死亡的候选药物用于NSCLC治疗,NQO1表达水平或可辅助筛选潜在获益人群。
- 联合GPX4抑制策略可能增强DHA诱导的铁死亡抗肿瘤效应,但需进一步临床验证。
局限性
- 机制验证主要基于A549和PC9细胞系及小鼠模型,尚未在临床样本中验证。
- NQO1过表达仅部分逆转DHA效应,提示可能存在其他靶点或通路参与。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dihydroartemisinin Engages NQO1 and Promotes Ferroptosis-Related Oxidative Stress in Non-Small Cell Lung Cancer. ABSTRACT Dihydroartemisinin (DHA), a bioactive derivative of Artemisia annua L. (AAL), has shown antitumor activity in several malignancies, including non-small cell lung cancer (NSCLC). However, the molecular determinants linking DHA exposure to ferroptosis in NSCLC remain incompletely understood. This study aimed to identify functionally relevant targets of DHA-associated ferroptotic stress and to investigate the role of NAD(P)H quinone dehydrogenase 1 (NQO1) in this process. An integrated network pharmacology and transcriptomic approach was used to identify ferroptosis-related candidate targets of A. annua. Molecular docking and molecular dynamics simulations were used for target prioritization, followed by surface plasmon resonance (SPR) and cellular thermal shift assay (CETSA) to evaluate the interaction between DHA and NQO1. The effects of DHA on ferroptosis-related phenotypes and redox homeostasis were examined in A549 and PC9 cells. NQO1 overexpression, NQO1 knockdown, and GPX4 rescue experiments were performed to assess pathway involvement. Antitumor activity and NQO1-associated effects were further evaluated in mouse tumor models. Network pharmacology identified 15 active components of AAL and 61 NSCLC-associated therapeutic targets enriched in ROS-related and ferroptosis-associated pathways. Among 10 ferroptosis-related core targets, NQO1 was prioritized based on disease relevance, predicted DHA interaction, selective protein suppression, and complementary computational and experimental evidence. DHA was selected for mechanistic validation based on its pharmacological relevance and anti-NSCLC activity. SPR supported direct DHA-NQO1 binding (KD = 7.61 × 10−6 M). Mechanistically, DHA suppressed NQO1 expression through transcriptional inhibition and enhanced protein degradation. DHA induced ferroptosis hallmarks, including ROS burst, LPO and Fe2+ accumulation, GSH/GSSG depletion, MDA elevation, and GPX4 inactivation, in A549 and PC9 cells. NQO1 overexpression partially reversed these effects, whereas NQO1 knockdown phenocopied DHA-induced ferroptotic responses. GPX4 overexpression partially rescued the ferroptotic phenotype induced by NQO1 depletion, supporting a functional link between NQO1 and the GPX4 antioxidant axis. In vivo, DHA suppressed tumor growth, an effect partially reversed by NQO1 overexpression. DHA triggers ferroptosis i
引用
- Phytotherapy Research:Dihydroartemisinin Engages NQO1 and Promotes Ferroptosis‐Related Oxidative Stress in Non‐Small Cell Lung Cancer
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。